65 results about "Blood pressure" patented technology

The application discloses a cardiovascular maintenance functional wine based on a composite fermentation process and a preparation method thereof. Through synergistic fermentation of rosewood flavones, five-grain nutrients and rhizoma notopterygii blood-activating components, a cardiovascular maintenance wine with multiple effects of blood pressure regulation, microcirculation improvement, nerve protection and anti-inflammation is developed. Process parameters are optimized and designed to ensure efficient reservation and release of active components, and the cardiovascular maintenance wine is suitable for daily auxiliary conditioning of sub-healthy people and cardiovascular risk groups.

The application discloses a blood purification device and a storage medium. The device comprises a memory and a processor. The memory stores a computer program, and the processor executes the computer program to realize the method. When the actual rotating speed of a first peristaltic pump detected is greater than a preset rotating speed, the pressure alarm range of an arterial pipeline and the pressure sampling period of a first pressure sensor are determined according to the actual rotating speed of the first peristaltic pump. The first pressure sensor is controlled to periodically sample the blood pressure of the arterial pipeline according to the pressure sampling period, and a plurality of continuous first detection pressures are obtained. Whether the first peristaltic pump is stopped is determined according to the first average pressure of the plurality of continuous first detection pressures and the pressure alarm range of the arterial pipeline. In this way, the application can more accurately and timely discover the pressure fault of the arterial pipeline, and improve the blood flow safety of the arterial pipeline.

This application relates to the field of blood pressure measurement, and discloses a blood pressure measurement method and system, an electronic device, and a medium. According to the blood pressure measurement method in this application, in a pressurization phase of blood pressure measurement, a real-time air pressure value of an air path connected to an air bladder is detected, and then an air valve drive circuit is controlled based on the real-time air pressure value. For example, when air pressure of the air bladder is low, a low drive voltage may be used to drive an air valve to operate; or when the air pressure of the air bladder is high, a high drive voltage may be used to drive the air valve to operate.

This application discloses a blood pressure measurement method, device, reminder and measurement method, wearable device, and readable storage medium, relating to the field of smart wearable device technology. The wearable device is equipped with an airbag and an air pump. The method includes: when the wearable device worn by the user is set with a timed reminder, determining a target time period before the trigger time based on the trigger time, wherein the trigger time is the moment when the timed reminder is triggered; acquiring the user's sleep state corresponding to the target time period; if the sleep state is sleep, controlling the air pump to inflate the airbag to measure the user's blood pressure data. By detecting the user's sleep state before the trigger time of the user-set timed reminder, and automatically measuring blood pressure when sleep is detected, the convenience and accuracy of blood pressure measurement are greatly improved.

This disclosure provides a method, apparatus, device, storage medium, and program product for testing non-invasive blood pressure measurement devices. The method includes extracting invasive blood pressure reference value features from test records based on a preset blood pressure assignment model, extracting pulse wave morphological features from test records, fusing the two features to obtain a multi-dimensional fused feature vector, calculating the multi-dimensional fused feature vector based on the blood pressure assignment model to obtain an invasive blood pressure prediction value, performing a numerical judgment on the invasive blood pressure test value based on the invasive blood pressure prediction value to obtain a numerical judgment result, generating the device accuracy status of the non-invasive blood pressure measurement device based on the numerical judgment result, and generating a test report of the non-invasive blood pressure measurement device containing evaluation conclusions according to a preset report template. This achieves personalized accuracy evaluation of non-invasive blood pressure measurement devices, improves evaluation reliability, reduces long-term dependence on invasive measurements, and forms a standardized evaluation closed loop.

This invention discloses a low-allergen compound oral liquid for middle-aged and elderly people that protects the liver, stabilizes blood pressure, blood sugar, and blood lipids, combats aging, aids sleep, and prevents Alzheimer's disease. It belongs to the field of food and medicine homology health food technology. The invention uses kudzu root extract, Japanese raisin tree fruit extract, mulberry leaf extract, jujube seed saponins, Acer truncatum seed oil (nervonic acid), blueberry anthocyanins, bitter melon small molecule peptides, wolfberry polysaccharides, γ-aminobutyric acid, and chrysanthemum flavonoids as core active ingredients, refined with a prebiotic system. This invention achieves comprehensive conditioning effects for middle-aged and elderly people through the synergistic action of five pathways: liver protection and metabolism, vascular regulation, anti-oxidation and anti-aging, nerve calming, and brain nerve repair. It simultaneously nourishes and protects the liver, stabilizes blood pressure, blood sugar, and blood lipids, delays aging, improves intractable insomnia, enhances memory, slows brain atrophy, and prevents Alzheimer's disease. This formula strictly avoids eight common allergens, is pure and mild, and contains no irritating additives, making it suitable for long-term use by middle-aged and elderly people with weak constitutions. This product is an oral liquid formulation, with small molecule extraction, strong permeability, rapid absorption, low gastrointestinal burden, stable production process, and high safety. It has extremely high clinical promotion value and industrialization prospects.

Methods, systems, and devices for synchronizing multiple devices for determining physiological metrics are described. A method may include flashing light-emitting diodes (LEDs) of a wearable device, and capturing images of the flashing LEDs using an imaging device. A synchronization procedure may be performed to identify a delay between internal clocks at the wearable device and the imaging device based on capturing the images. Subsequently, the wearable device and the imaging device may collect physiological data at different physiological locations on the user's body, where the physiological data includes separate pulse observation times of a heartbeat of the user at the different physiological locations. Subsequently a pulse transmit time (PTT) associated with the heartbeat may be determined based on the delay and a comparison between the pulse observation times, and a blood pressure metric for the user is determined based on the PTT.

A method of regulating blood pressure in a subject is provided. The method comprises administering a preparation comprising ammonia oxidizing microorganisms to the subject, thereby regulating blood pressure in the subject. Related preparations, kits, and devices are also provided.

A method for operating a blood pressure measuring apparatus includes the steps of: applying a measuring apparatus, containing a pressure unit and / or a pressure measuring unit, to a measurement point on the body; initialising the measuring apparatus by carrying out a reference measurement and / or by carrying out defined position changes to the measurement point and determining person-specific initialisation parameters; storing the person-specific initialisation parameters in a memory and control unit; carrying out at least one blood pressure measurement by applying a counter pressure to the pressure unit in a sub-systolic low-pressure range; maintaining the applied counter pressure within a plateau phase having a predefined duration and recording blood pressure time curve data during the predefined duration; converting the recorded blood pressure time curve data over the initialisation parameters into arterial blood pressure data over time.

1. Name of the product in this design: Pre-adaptation training device (BB-RIC-Q5). 2. Purpose of this design: for ischemic preconditioning training and blood pressure measurement. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: a 3D model.

This invention discloses an oral liquid for middle-aged and elderly men to cleanse blood, protect the brain, and promote hair growth, as well as its preparation method, belonging to the field of functional health food technology. Each bottle contains 50ml net content, one bottle daily, and is free of eight major allergens. The ingredients include resistant dextrin, erythritol, DHA algal oil microcapsule powder, phosphatidylserine, natto freeze-dried powder, various medicinal and edible extracts, ginseng, vitamins, folic acid, and purified water. This invention upgrades a solid beverage into an easily absorbed oral liquid dosage form, which is rapidly absorbed, does not harm the stomach and intestines, and can cleanse blood vessels, purify blood, assist in regulating blood pressure, blood sugar, and cholesterol, prevent and intervene in Alzheimer's disease, improve memory, and promote hair growth and darkening. The production process is mature and stable, suitable for industrial production, and is specially designed for middle-aged and elderly men, making it safe for long-term consumption.

The present application provides a propofol analogue, a preparation method thereof and application thereof in non-narcotic field. The propofol analogue has a structure as shown in general formula (G). The propofol analogue of the present application can greatly reduce or eliminate the affinity to GABA receptor, i.e. weaken or eliminate the narcotic property. It targets specific targets and shows effects in improving sleep, regulating blood pressure, relieving vomiting, resisting depression, protecting heart and brain, etc. (G).

The invention provides an implantable wireless electrocardio detection device, and relates to the field of in-vivo implantable devices, the implantable wireless electrocardio detection device comprises a shell and a plurality of electrodes, the plurality of electrodes are arranged on the shell, the monitoring ends of the plurality of electrodes are exposed on the surface of the shell, and the plurality of electrodes are used for collecting subcutaneous electrocardio signals; the circuit board is arranged in the shell, a processor and a memory are integrated on the circuit board, and the electrodes are electrically connected with the memory; the induction coil is arranged in the shell and electrically connected with the circuit board, and the induction coil is configured to receive a wireless pressure signal sent by a blood pressure sensor implanted in the heart; the processor is configured to store wireless pressure signals received by the induction coil and electrocardiosignals collected by the electrodes into the storage. According to the technical scheme, a high-synchronism original data basis is provided for follow-up analysis of the relevance between heart electrical activity and hemodynamics, such as evaluation of the influence of arrhythmia on blood pressure, and the capacity of comprehensive monitoring and diagnosis of cardiovascular diseases is remarkably enhanced.

This invention discloses a method for extracting chlorogenic acids from stevia waste and its applications, including: extracting chlorogenic acids from stevia powder using an alkaline extraction method; and determining whether the chlorogenic acids contain chlorogenic acid, isochlorogenic acid A, and cryptochlorogenic acid. Using stevia waste as raw material, this invention involves solvent extraction, centrifugal filtration, reflux extraction, and chromatographic separation to obtain a fat-soluble extract. This extract is then dissolved and filtered with ethanol, evaporated and concentrated, and freeze-dried to obtain the chlorogenic acid product. This invention extracts and develops chlorogenic acids from stevia waste, solving the problems of environmental pollution and resource waste. The extracted chlorogenic acids contain chlorogenic acid, cryptochlorogenic acid, and isochlorogenic acid A, and have low sugar content. They possess antioxidant, anti-inflammatory, and blood pressure-lowering functions, and can be widely used in food, pharmaceuticals, and health products, demonstrating high application value and realizing the comprehensive utilization of stevia.

The application provides a synchronous continuous blood pressure signal and electroencephalogram coupling analysis method, which comprises the following steps: a synchronous signal preprocessing step; preprocessing the synchronous continuous blood pressure signal and single-channel electroencephalogram to obtain a clean continuous blood pressure signal and a clean electroencephalogram; a continuous blood pressure signal feature detection and processing step; identifying the peak points of the blood pressure waveform of each cycle of the clean continuous blood pressure signal; each peak point corresponds to a systolic pressure anchor point; an evoked potential construction step; taking each systolic pressure anchor point as a reference, intercepting a clean electroencephalogram of a predetermined length from the clean electroencephalogram to form an intercepted segment; aligning and averaging all the intercepted segments to obtain a systolic pressure evoked potential; and a fatigue evaluation index calculation step; using a P300 paradigm to analyze the systolic pressure evoked potential to obtain a systolic pressure evoked potential P300 response as a fatigue evaluation index.

An air pump assembly (220), a gauge head mechanism (200), a wearable device (10), and a blood pressure detection apparatus and method. The air pump assembly (220) comprises: an air pump (221), a first main control valve (222), a second main control valve (223), and an air release valve (224). The air pump (221) is in communication with the first main control valve (222) and the second main control valve (223) by means of a main air path (2201), and is provided with a first vent port (2211) in communication with the main air path (2201) and the external atmosphere, and the first vent port (2211) is openable or closable. The first main control valve (222) is provided with a first air port (2221) in communication with the main air path (2201) and a first external air path (202), and the first air port (2221) is openable or closable. The second main control valve (223) is provided with a second air port (2231) in communication with the main air path (2201) and a second external air path (203). The second air port (2231) is openable or closable. The first external air path (202) is independent of the second external air path (203). The air release valve (224) is provided with a second vent port (2241) in communication with the first external air path (202) and the external atmosphere, and the second vent port (2241) is openable or closable. The air pump and the air release valve can serve as backup valves for each other to perform air release, so that the first external air path has a redundant air release path, thereby improving the use safety of the air pump assembly.

This program provides support for detecting early signs of atrial fibrillation, enabling easy estimation of these signs. [Solution] The atrial fibrillation prediction support program of this disclosure includes a blood pressure measurement information acquisition procedure, a prediction estimation procedure, and an output procedure, The aforementioned blood pressure measurement information acquisition procedure acquires the blood pressure measurement information of the subject, The aforementioned precursor estimation procedure estimates the precursor of atrial fibrillation in the subject based on the blood pressure measurement information, The output procedure outputs the estimated results of the atrial fibrillation precursor.

1. Name of the product in this design: Display area of ​​the graphical user interface for information display on electronic devices. 2. Purpose of this design: An electronic device. 3. The key design features of this product are the graphical user interface in the electronic device for which protection is sought. 4. The picture or photo that best illustrates the key design points: Design 1 front view. 5. Design 1 is designated as the basic design. 6. Purpose of the graphical user interface: The graphical user interface is used to display blood pressure information and medication guidance information. The graphical user interface requests protection for a portion used to display blood pressure information and medication instructions. 7. Human-computer interaction method of graphical user interface: In response to the user swiping up the information display area in the main view of Design 1, the graphical user interface changes from the main view of Design 1 to the change state diagram of Design 1 to display medication guidance information. In response to the user swiping up the information display area in the main view of Design 2, the graphical user interface changes from the main view of Design 2 to the change state diagram of Design 2 to display medication guidance information. 8. Other situations requiring explanation: The portions of the graphical user interface shown by the dashed lines in the views of Design 1 and Design 2 do not constitute the parts protected by this design.

An implantable sensor system using one or more sensor implants comprised of micro-electrical mechanical system (MEMS) sensors for the accurate and continuous measurement of physiological hemodynamic signals such as diastolic and systolic blood pressure. Sensor implants are configured to be subcutaneously injected to a placement site adjacent a blood vessel. In some embodiments, sensors comprise micromachined ultrasonic transducers.

The embodiment of the present application provides a breathing training method and related equipment, which can provide tactile feedback when a user performs breathing training, so that the user can focus on breathing itself, and provides an immersive breathing training experience for the user. Moreover, the embodiment of the present application can complete the measurement of physiological parameters such as blood pressure during the breathing training process, and feed back the breathing training effect. Wherein, the tactile feedback can be generated based on the air bag on the wearable device, and the pressure in the air bag can be changed through inflation and deflation, so as to generate tactile stimulation. In addition to providing tactile feedback, the air bag on the wearable device can also be used for blood pressure measurement. In this way, the embodiment of the present application can realize the two-in-one of tactile feedback and blood pressure measurement based on the air bag on the wearable device, save the design cost, and avoid additional hardware requirements.

1. Name of the product in this design: Blood Pressure Workstation (X80). 2. Purpose of this design: To detect and analyze human blood pressure, pulse, and blood oxygen. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: a 3D model.

The present invention relates to methods of reducing weight, HbA1c levels, high-sensitivity C-reactive protein, and systolic blood pressure in human patients comprising administering to the patient maridebart cafraglutide with the result being treatment of obesity, type II diabetes, and other obesity related conditions such as atherosclerotic cardiovascular disease and heart failure.

The present invention provides an injectable depot composition comprising linagliptin and low-dose liraglutide. The combination therapy of linagliptin and low-dose liraglutide provides a synergistic effect in the treatment of obesity compared to the administration of each drug alone. In addition, the administration dose of liraglutide can be reduced compared to the administration of liraglutide alone, and thus the direct cause of side effects related to the gastrointestinal system and the cardiovascular system of liraglutide can be reduced. Furthermore, by the combination of linagliptin, it has the advantage of additionally providing an improvement effect on metabolic diseases and cardiovascular diseases related to blood sugar, blood lipids, blood pressure, fatty liver, etc. In addition, compared to the conventional liraglutide dosage form of once-daily subcutaneous injection, the depot composition of linagliptin and liraglutide of the present invention can significantly improve patient convenience and patient compliance by unifying the administration route and improving the administration cycle.

FIELD: medical technology.SUBSTANCE: claimed group of inventions can be used to determine blood pressure based on pulse wave parameters. The following are proposed: a method for training a neural network, a method for further training a neural network, and a method for determining the blood pressure indicator of a wearable device user. Parameters for the anacrotic and dicrotic components of the pulse wave are predicted, the pulse wave is reconstructed, blood pressure readings are predicted, and loss functions are calculated for predicting the pulse wave and for predicting blood pressure readings. The resulting pulse wave is the pointwise sum of the reconstructed anacrotic component of the pulse wave and the reconstructed dicrotic component of the pulse wave.EFFECT: determination of the systolic or diastolic blood pressure of the user at any time using a wearable device, whereas the user is not required to systematically recalibrate the blood pressure value using a tonometer.6 cl, 9 dwg

The application discloses a theobromine-containing composition and a preparation method and application thereof. The application provides the theobromine-containing composition which comprises the following raw materials in mass fractions: 10-50 parts of microcrystalline cellulose, 0.5-5 parts of inorganic salt, 5-30 parts of theobromine, 1-20 parts of vitamin, 0.2-10 parts of sweetening agent, 1-10 parts of inorganic base, 2-20 parts of sugar alcohol, 2-20 parts of essence, 2-20 parts of humectant and 0.1-2 parts of cooling agent, with the total weight of all the raw materials being 100 parts. The theobromine-containing composition has good taste, rapid absorption, long-lasting effect, convenient carrying and good bioavailability. The theobromine-containing composition has a good application prospect in refreshing and blood pressure reducing products.

This application provides an air pump assembly, a meter mechanism, a wearable device, a blood pressure detection device, and a method. The air pump assembly includes: an air pump, a first main control valve, a second main control valve, and a vent valve. The air pump is connected to the first and second main control valves via a main air path and has a first vent port connecting the main air path and the external atmosphere, which can be opened or closed. The first main control valve has a first air port connecting the main air path and a first external air path, which can be opened or closed. The second main control valve has a second air port connecting the main air path and the second external air path, which can be opened or closed. The first external air path is independent of the second external air path. The vent valve has a second vent port connecting the first external air path and the external atmosphere, which can be opened or closed. Through the above configuration, the air pump and the vent valve can serve as backup valves for each other, providing redundant venting paths for the first external air path and improving the safety of the air pump assembly.

The present invention provides an obesity treatment regimen for reducing side effects by low-dose combination administration of linagliptin and liraglutide. The combination therapy of linagliptin and low-dose liraglutide provides a synergistic effect in obesity treatment compared to administration of each drug alone. Furthermore, the administration dose of liraglutide can be reduced compared to administration of liraglutide alone, and thus the direct cause of side effects related to the gastrointestinal system and the cardiovascular system of liraglutide can be reduced. Furthermore, by the combination of linagliptin, it has the advantage of additionally providing an improvement effect on metabolic diseases and cardiovascular diseases related to blood sugar, blood lipids, blood pressure, fatty liver, etc.